-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On Saturday, October 17th, the official website of the Health Insurance Administration issued an announcement on the results of the review of the 2020 National Health Insurance Drug Catalog Adjustment Form. The contents of the
announcement reveal two aspects of information: First, the "2020 National Health Insurance Drug Catalog Adjustment Through Formal Review of the List of Declared Medicines (Public Draft)" released to the public on September 18th, is not the final formal review, that is, the list of experts who will be eligible for the next round of health care catalog adjustments and negotiations.
, the current process of adjusting the health-care directory lags slightly behind previous programs.
Because according to the 2020 National Health Insurance Drug Catalog Adjustment Work Programme previously published by the Health Insurance Administration, this year's health care catalog adjustment is divided into five stages: preparation, declaration, expert review, negotiation and bidding, and publication of the results.
, the negotiation and bidding phase is completed between October and November, with the results announced at 12 November.
has been in progress for more than half in October and is currently under way in the reporting phase (August-September 2020), which, as described in the programme, includes the publication of reporting guidelines.
the scope of the 2020 drug catalog adjustment, the recipient of eligible declaration subjects to submit the necessary information to the National Health Insurance Administration Medical Insurance Center in accordance with the provisions.
to conduct a formal review of the information and to make public medicines that have passed the formal review.
so, according to the number of review lists published in its current form, if expert reviews, negotiations and bids are completed in October, either the negotiation cycle will be extended or more health care experts will be involved.
